Article
Obstetrics & Gynecology
Richard H. Lee, Mara Greenberg, Torri D. Metz, Christian M. Pettker
Summary: Intrahepatic cholestasis of pregnancy can cause maternal itching symptoms and pose potential risks for the fetus. Regular monitoring of bile acid and liver enzyme levels, medication treatment, and timely antenatal fetal surveillance are recommended.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
(2021)
Article
Obstetrics & Gynecology
Xiaomei Huang, Lei Lei, Fan Feng, Yong Shao
Summary: This study investigated the distribution of lipopolysaccharide in the maternal body and its effect on fetal outcomes in mice with intrahepatic cholestasis of pregnancy. The results showed significantly elevated levels of lipopolysaccharide in women with intrahepatic cholestasis of pregnancy, and in vivo fluorescence imaging revealed higher intensity of lipopolysaccharide in mice with intrahepatic cholestasis of pregnancy. Ursodeoxycholic acid and resveratrol treatment effectively reduced lipopolysaccharide levels in pregnant mice with intrahepatic cholestasis of pregnancy.
BMC PREGNANCY AND CHILDBIRTH
(2022)
Article
Gastroenterology & Hepatology
Tharni Vasavan, Sahil Deepak, Indu Asanka Jayawardane, Maristella Lucchini, Catherine Martin, Victoria Geenes, Joel Yang, Anita Lovgren-Sandblom, Paul Townsend Seed, Jenny Chambers, Sophia Stone, Lesia Kurlak, Peter Hendy Dixon, Hanns-Ulrich Marschall, Julia Gorelik, Lucy Chappell, Pam Loughna, Jim Thornton, Fiona Broughton Pipkin, Barrie Hayes-Gill, William Paul Fifer, Catherine Williamson
Summary: Elevated fetal and maternal serum bile acid concentrations in untreated ICP are associated with an abnormal fetal cardiac phenotype characterized by increased NT-proBNP concentration, PR interval length and HRV. UDCA treatment partially attenuates this phenotype.
JOURNAL OF HEPATOLOGY
(2021)
Article
Obstetrics & Gynecology
J. Fleminger, P. T. Seed, A. Smith, E. Juszczak, P. H. Dixon, J. Chambers, J. Dorling, C. Williamson, J. G. Thornton, L. C. Chappell
Summary: The study found that there was no specific group of women with intrahepatic cholestasis of pregnancy who would benefit from treatment with ursodeoxycholic acid, indicating that its routine use for improvement of bile acid concentration or itch score should be reconsidered.
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
(2021)
Article
Gastroenterology & Hepatology
Diletta Overi, Guido Carpino, Laura Cristoferi, Paolo Onori, Lindsey Kennedy, Heather Francis, Nicola Zucchini, Cristina Rigamonti, Mauro Vigano, Annarosa Floreani, Daphne D'Amato, Alessio Gerussi, Rosanna Venere, Gianfranco Alpini, Shannon Glaser, Domenico Alvaro, Pietro Invernizzi, Eugenio Gaudio, Vincenzo Cardinale, Marco Carbone
Summary: Extensive ductular reaction is associated with disease stage, liver fibrosis, treatment response, and prognosis in patients with primary biliary cholangitis (PBC). The establishment of ductular-canalicular junctions and fibrogenetic cell activation are observed in PBC patients with reactive ductules. Ursodeoxycholic acid treatment reduces ductular reaction and fibrosis and increases ductular-canalicular junctions in a mouse model of intrahepatic cholestasis.
Review
Obstetrics & Gynecology
Chidera Nneji Obiegbusi, Xiao Jing Dong, Samuel Chigbo Obiegbusi, Xiao Jin, Innocent Kenechukwu Okoene
Summary: This review summarizes the existing evidence on predictors of adverse fetal outcomes in pregnant women diagnosed with intrahepatic cholestasis of pregnancy (ICP). The identified predictors include in vitro fertilization (IVF) pregnancy, multifetal pregnancy, biochemical markers, gestational age of ICP onset, presence of comorbidities, maternal history of ICP, and hepatobiliary disease.
REPRODUCTIVE SCIENCES
(2023)
Article
Genetics & Heredity
Przemyslaw Kosinski, Malgorzata Kedzia, Adrianna Mostowska, Pawel Gutaj, Michal Lipa, Ewa Wender-Ozegowska, Adriana Rozy, Joanna Chorostowska-Wynimko, Miroslaw Wielgos, Aleksandra Jezela-Stanek
Summary: The study revealed an increased prevalence of the SERPINA1 PI*Z variant in women with intrahepatic cholestasis, suggesting a possible genetic origin of a higher risk of intrahepatic cholestasis in pregnancy.
FRONTIERS IN GENETICS
(2021)
Review
Pharmacology & Pharmacy
Dan Shan, Siyu Dai, Qian Chen, Yupei Xie, Yayi Hu
Summary: This article reviews the current clinical evidence on the application of hepatoprotective agents in intrahepatic cholestasis of pregnancy (ICP) patients. The underlying physiological mechanisms and therapeutic effects of these agents in clinical practice are summarized. Limited clinical data demonstrate the reliable effectiveness and safety of these medications in ICP patients.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Medicine, General & Internal
Gal Hershkovitz, Yael Raz, Ilana Goldinger, Ariel Many, Liran Hiersch, Rimon Eli
Summary: Intrahepatic cholestasis of pregnancy (ICP) is characterized by elevated total bile acids (TBA). It is unclear why some fetuses are more prone to the hazardous effect of bile acids (BA) over the others. We aimed to compare TBA levels in umbilical vein and artery to maternal TBA in women with ICP. The study included 18 women and 23 fetuses, and we found that the TBA level in umbilical vein was significantly lower compared to maternal TBA level.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Obstetrics & Gynecology
William M. Hague, Leonie Callaway, Jennifer Chambers, Lucy Chappell, Suzette Coat, Jiska de Haan-Jebbink, Marloes Dekker, Peter Dixon, Jodie Dodd, Maria Fuller, Sanne Gordijn, Dorothy Graham, Oskari Heikinheimo, Annemarie Hennessy, Risto Kaaja, Teck Yee Khong, Laura Lampio, Jennie Louise, Angela Makris, Corey Markus, Hanns-Ulrich Marschall, Philippa Middleton, Ben W. Mol, Jonathan Morris, John P. Newnham, Caroline Ovadia, Michael Peek, Antonia Shand, Michael Stark, Jim Thornton, Susanna Timonen, Susan Walker, David Warrilow, Catherine Williamson
Summary: Severe early onset intrahepatic cholestasis of pregnancy (ICP) affects 0.1% of pregnant women in Australia, with limited treatment options such as ursodeoxycholic acid (UDCA) and rifampicin. This study will be the first to examine the outcomes of treatment specifically in the severe early onset form of ICP, comparing the efficacy of rifampicin and UDCA, providing high-quality evidence for rifampicin use.
BMC PREGNANCY AND CHILDBIRTH
(2021)
Review
Gastroenterology & Hepatology
Rebecca Roediger, Jaquelyn Fleckenstein
Summary: Intrahepatic cholestasis of pregnancy (ICP) is a common disorder in the second half of pregnancy with risks of adverse effects on the fetus. Although genetically susceptible, there is currently no proven preventive method, and ursodeoxycholic acid remains the first-line treatment option.
SEMINARS IN LIVER DISEASE
(2021)
Article
Obstetrics & Gynecology
Manuel Guerra, Ignacio Montano, Maria T. Haye, Victoria Toro, Nerea Maiz
Summary: This study found differences in fetal cardiac function between patients with and without ICP, with a longer PR interval in fetuses of women with ICP. There was a significant correlation between PR interval and bile acid levels, and administration of UDCA significantly reduced PR interval.
AMERICAN JOURNAL OF PERINATOLOGY
(2023)
Review
Obstetrics & Gynecology
Antonio F. Saad, Luis D. Pacheco, Lucy Chappell, George R. Saade
Summary: ICP is associated with poor perinatal outcomes in some women, but recent evidence shows that UDCA may not have a significant impact on most perinatal outcomes, therefore a comprehensive approach is needed to manage ICP effectively.
REPRODUCTIVE SCIENCES
(2022)
Review
Gastroenterology & Hepatology
Michal Prokopic, Ulrich Beuers
Summary: PSC is a rare liver disease characterized by bile duct abnormalities leading to liver fibrosis and potential cholangiocarcinoma. The exact pathogenesis is still unclear, with strong association with inflammatory bowel disease. Current medical treatments have not been proven effective, with liver transplantation remaining the most viable option for late-stage disease.
HEPATOLOGY INTERNATIONAL
(2021)
Article
Pediatrics
Hilde D. de Vries, Anna Palmiotti, Rumei Li, Milaine Hovingh, Niels L. Mulder, Martijn Koehorst, Vincent W. Bloks, Tim van Zutphen, Folkert Kuipers, Jan Freark de Boer
Summary: Perinatal exposure to UDCA can prevent neonatal cholestasis in Cyp2c70(-/-) mice, but has no long-lasting effects on liver pathophysiology.
PEDIATRIC RESEARCH
(2023)
